Oral agents and Outpatient Injections
FUNDING:
Medications that are taken at home may be covered by the provincial drug benefit plan or by private insurance plans.
FORMULARIES:
RAMQ List of Medications: Click Here
Drug (Brand Name) Manufacturer |
Indication | Strength, Route | DIN | Provincial Funding Eligibility Criteria | References | Patient Assistance Programs |
---|---|---|---|---|---|---|
Abiraterone (Zytiga) Janssen Inc. | mCSPC | - |
- |
No listing as of Mar. 2022 |
- |
Janssen (Janssen BioAdvance Patient Assistance Program): https://www.bioadvancemember.ca/s/reimbursement-support?language=en_US |
Abiraterone (Zytiga) Janssen Inc. | mCRPC | 250 mg PO / 500 mg PO |
Multiple |
Exceptional medication with recognized indications for payment Eligibility1:
Notes1:
|
|
Janssen (Janssen BioAdvance Patient Assistance Program): https://www.bioadvancemember.ca/s/reimbursement-support?language=en_US |
Abiraterone Generic | mCSPC | - |
- |
No listing as of Mar. 2022 / Non répertorié en mars 2022 |
|
JAMP (JAMP Care): https://jampcare-support.ca/en/index.html
Sentrex Health Solutions: https://sentrex.com/patient-programs/
Pharma-science: https://www.pharmascience.com/en/patient-support-programs/
Apotex: |
Abiraterone Generic | mCRPC | 250 mg PO 500 mg PO |
Multiple |
Exceptional medication with recognized indications for payment
Eligibility1: For patients with mCRPC, in combination with prednisone
Notes1:
Remarques1: La durée maximale de chaque autorisation est de 4 mois. Lors des demandes pour la poursuite du traitement, le médecin devra fournir la preuve d’un effet clinique bénéfique par l’absence de progression de la maladie. Il est à noter que l’abiratérone n’est pas autorisée à la suite d’un échec avec un inhibiteur de la synthèse des androgènes ou un inhibiteur du récepteur des androgènes de seconde génération s’ils ont été administrés pour le traitement du cancer de la prostate. Toutefois, l’abiratérone demeure couverte par le Régime général d’assurance médicaments pour les personnes assurées ayant utilisé ce médicament au cours des 3 mois précédant le 10 juillet 2019, en autant que le médecin fournisse la preuve d’un effet bénéfique par l’absence de la progression de la maladie.
|
|
JAMP (JAMP Care): https://jampcare-support.ca/en/index.html
Sentrex Health Solutions: https://sentrex.com/patient-programs/
Pharma-science: https://www.pharmascience.com/en/patient-support-programs/
Apotex: |
Alendronate Generic | Osteoporosis | 5 mg PO | 10 mg PO | 70 mg PO |
Multiple |
|
|
Apotex: Access Here |
Apalutamide (Erleada) Janssen Inc. | nmCRPC | Tablet, PO, 60mg, 240mg |
60mg: 02478374 240mg: 02540185 |
Exceptional medication Eligibility1:
Notes1:
|
|
Janssen BioAdvance Patient Assistance Program: Access Here |
Apalutamide (Erleada) Janssen Inc. | mCSPC | Tablet, PO, 60mg, 240mg |
60mg: 02478374 240mg: 02540185 |
Exceptional medication Eligibility: In association with ADT, for the treatment of mCSPC, in persons:
Notes:
**60 mg tablet funded, 240 mg tablet pending provincial funding decision |
|
Janssen BioAdvance Patient Assistance Program: Access Here |
Darolutamide (Nubeqa) Bayer | nmCRPC | 300 mg PO |
02496348 |
Quebec Exceptional Medication For treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), in persons:
|
|
NUBEQA® DART Patient Support Program: Toll free: 1-833-955-3278 Fax: 1-877-208-4393 Email:
|
Darolutamide (Nubeqa) Bayer | mCSPC | 300 mg PO |
02496348 |
Exceptional medication Eligibility:
|
NUBEQA® DART Patient Support Program: Toll free:1-833-955-3278 Fax:1-877-208-4393 Email: info@dartsupport.ca |
|
Denosumab (Jubbonti) Sandoz | Non-metastatic prostate cancer receiving ADT + high bone fracture risk | 60 mg / Syr Injection |
02545411 |
Pending |
|
Haven: |
Denosumab (Prolia) Amgen | Osteoporosis | S.C. Inj. Sol. (syr) 60 mg/ml |
02343541 |
Exceptional medication Eligibility1:
|
|
ProVital Program: Access Here |
Denosumab (Wyost) Sandoz | mCRPC + high risk of skeletal-related events | Inj. Sol. |
02545764 |
Pending |
|
Haven: |
Denosumab (Xgeva) Amgen | mCRPC + Bone mets | Inj. Sol. 120 mg /1.7mL |
02368153 |
Exceptional medication Eligibility1:
|
|
The VICTORY Program: Access Here |
Enzalutamide (Xtandi) Astellas | nmCRPC | 40 mg capsule |
02407329 |
For treatment of non-metastatic castration-resistant prostate cancer, in persons:
and
The maximum duration of each authorization is four months
When requesting continuation of treatment, the physician must provide evidence of a beneficial clinical effect defined by the absence of disease progression |
RAMQ List of Exceptional Medications With Recognized Indications for Payment |
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (Français)
|
Enzalutamide (Xtandi) Astellas | mCSPC | 40 mg capsule |
02407329 |
In association with an androgen deprivation therapy (ADT), for treatment of metastatic castration-sensitive prostate cancer, in persons whose ECOG performance status is 0 or 1:
or
The maximum duration of each authorization is four months.
When requesting continuation of treatment, the physician must provide evidence of a beneficial clinical effect by the absence of disease progression.
It must be noted that enzalutamide is not authorized following failure with an androgen synthesis inhibitor or a second-generation androgen receptor inhibitor if they have been administered to treat prostate cancer. |
RAMQ List of Exceptional Medications With Recognized Indications for Payment |
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (Français) |
Enzalutamide (Xtandi) Astellas | mCRPC | 40 mg PO |
02407329 |
Exceptional medication Eligibility1:
Notes1:
|
|
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (Français)
|
Niraparib and abiraterone acetate (AKEEGA®) Janssen Inc. | mCRPC | Dual-action tablet, PO/ Comprimé à double action, PO: 100mg niraparib/500mg abiraterone acetate |
02538563 |
Pending provincial funding decision |
N/A |
Janssen BioAdvance Patient Assistance Program: Access Here |
Olaparib (Lynparza) AstraZeneca | mCRPC | 100 mg tab | 150 mg tab |
100mg: 02475200 | 150mg: 02475219 |
Listed as of April 2022 Recognized indication for payment
Each authorization is for a maximum period of 4 months.
When requesting continuation of treatment, proof of a clinical benefit by the absence of disease progression must be provided. |
- |
AstraZeneca Patient Support Program: Access Here |
Orgovyx (Relugolix) Sumitomo Pharma Canada | Advanced CRPC/CSPC | 200/400mg tablet |
02542137 |
Pending (Positive CDA decision: relugolix | CDA-AMC) |
|
Copay cards available from manufacturer |